Lys240
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys240  -  GTF2I (human)

Site Information
EMAAVtVkEESEDPD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15282907

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 3 , 4 ) , mutation of modification site ( 2 )
Disease tissue studied:
liver cancer ( 2 ) , hepatocellular carcinoma ( 2 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on GTF2I:
molecular association, regulation ( 2 )
Effects of modification on biological processes:
carcinogenesis, induced ( 2 ) , cell growth, induced ( 2 )
Inhibit interaction with:
HDAC3 (human) ( 2 )

References 

1

Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171
29079793   Curated Info

2

Tu J, et al. (2015) Functional Proteomics Study Reveals SUMOylation of TFII-I is Involved in Liver Cancer Cell Proliferation. J Proteome Res 14, 2385-97
25869096   Curated Info

3

Tammsalu T, et al. (2014) Proteome-wide identification of SUMO2 modification sites. Sci Signal 7, rs2
24782567   Curated Info

4

Possemato A (2010) CST Curation Set: 9357; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: smK
Curated Info